QIAGEN (QGEN) said late Tuesday it has received clearance from the US Food and Drug Administration for the use of its gastrointestinal panels on the QIAstat-Dx Rise automated syndromic testing system.

Following the health regulator's approval, laboratories in the US can run respiratory and gastrointestinal panels on the higher-throughput automated platform, the company said.